Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results Article

cited authors

  • Amin, Asim; Dudek, Arkadiusz Z.; Logan, Theodore F.; Lance, Raymond S.; Holzbeierlein, Jeffrey M.; Knox, Jennifer J.; Master, Viraj A.; Pal, Sumanta K.; Miller, Wilson H., Jr.; Karsh, Lawrence I.; Tcherepanova, Irina Y.; DeBenedette, Mark A.; Williams, W. Lee; Plessinger, Douglas C.; Nicolette, Charles A.; Figlin, Robert A.

authors

Publication Date

  • April 21, 2015

webpage

published in

category

keywords

  • AGS-003
  • Dendritic cell
  • Immunotherapy
  • RCC
  • Sunitinib

volume

  • 3